GLP-1 receptor agonists provide modest reductions in blood pressure, making them beneficial adjuncts for managing hypertension in patients with diabetes and obesity.
Do GLP-1 RAs reduce blood pressure in patients with hypertension, diabetes, and obesity?
GLP-1 RAs offer modest blood pressure reductions alongside significant metabolic and cardiovascular benefits, making them a valuable adjunctive therapy for hypertensive patients with diabetes or obesity.
Absolute Event Rate: 0% vs 0%
Hypertension is a prominent cardiovascular risk factor, especially among patients with diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of drugs originally developed to improve glycemic control in patients with diabetes; however, these agonists have subsequently demonstrated additional cardioprotective effects, including modest reductions in blood pressure (BP). This literature review examines the various mechanisms through which GLP-1 RAs reduce BP, including weight loss, improved endothelial function, and renal sodium management. While GLP-1 RAs are less potent in BP reduction compared to conventional antihypertensive agents, the broader metabolic benefits of these agonists make this class of drug a valuable adjunct in managing hypertension, particularly in patients with metabolic syndrome. Nonetheless, further studies are needed to explore the long-term effects of BP and optimize patient selection for maximal cardiovascular benefit.
Gala et al. (Thu,) reported a other. GLP-1 receptor agonists provide modest reductions in blood pressure, making them beneficial adjuncts for managing hypertension in patients with diabetes and obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: